Frank Aquila Explains Why Big Pharma M&A Is Having a Record-Breaking Start in 2018

January 22, 2018
Read More

Frank Aquila was quoted in the Financial Times article “Big Pharma makes strongest start to M&A for a decade,” reporting on the almost $30 billion of acquisitions by healthcare companies since the beginning of 2018. “As Big Pharma is confronted with drugs going off patent and weak research and development pipelines, they have no choice but to do significant acquisitions despite pushing valuation metrics,” Frank said. “The new US tax law puts more cash in buyers' hands and lower rates make more deals accretive. It's a powerful combination.”